Edwards Lifesciences Corp. (EW) Hits New 12-Month High at $119.39

edwards-lifesciences-corp-ew-hits-new-12-month-high-at-11939.gif

Shares of Edwards Lifesciences Corp. (NYSE:EW) reached a new 52-week high on Wednesday . The company traded as high as $119.39 and last traded at $119.17, with a volume of 881,072 shares traded. The stock had previously closed at $117.42.
A number of analysts recently weighed in on the company. JMP Securities restated a “mkt perform” rating on shares of Edwards Lifesciences Corp. in a research report on Wednesday, June 1st. Canaccord Genuity restated a “buy” rating and issued a $132.00 target price on shares of Edwards Lifesciences Corp. in a research report on Wednesday, June 1st. Jefferies Group restated a “buy” rating and issued a $125.00 target price on shares of Edwards Lifesciences Corp. in a research report on Wednesday, July 27th. Citigroup Inc. lifted their price target on Edwards Lifesciences Corp. from $86.00 to $94.00 and gave the stock a “sell” rating in a research note on Wednesday, July 27th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $120.00 price target on shares of Edwards Lifesciences Corp. in a research note on Wednesday, July 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the company’s stock. Edwards Lifesciences Corp. presently has a consensus rating of “Buy” and an average price target of $118.13.
The stock’s 50-day moving average price is $115.27 and its 200 day moving average price is $104.45. The firm has a market cap of $25.37 billion, a PE ratio of 49.24 and a beta of 0.60.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/edwards-lifesciences-corp-ew-hits-new-12-month-high-at-119-39.html

Edwards Lifesciences Corp. (NYSE:EW) last released its quarterly earnings data on Tuesday, July 26th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.70 by $0.06. The company had revenue of $759.30 million for the quarter, compared to the consensus estimate of $724.26 million. Edwards Lifesciences Corp. had a return on equity of 23.72% and a net margin of 19.26%. Edwards Lifesciences Corp.’s quarterly revenue was up 23.1% on a year-over-year basis. During the same period last year, the business posted $0.57 EPS. On average, analysts predict that Edwards Lifesciences Corp. will post $2.88 EPS for the current year.
In other Edwards Lifesciences Corp. news, VP Larry L. Wood sold 13,257 shares of the firm’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $98.79, for a total transaction of $1,309,659.03. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Huimin Wang sold 13,650 shares of the firm’s stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $98.44, for a total value of $1,343,706.00. The disclosure for this sale can be found here. Company insiders own 2.37% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its position in Edwards Lifesciences Corp. by 2.3% in the second quarter. Quadrant Capital Group LLC now owns 1,108 shares of the medical research company’s stock valued at $106,000 after buying an additional 25 shares during the last quarter. Sigma Planning Corp increased its position in Edwards Lifesciences Corp. by 1.2% in the second quarter. Sigma Planning Corp now owns 2,609 shares of the medical research company’s stock valued at $260,000 after buying an additional 31 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its position in Edwards Lifesciences Corp. by 1.1% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 5,451 shares of the medical research company’s stock valued at $489,000 after buying an additional 60 shares during the last quarter. HighTower Advisors LLC increased its position in Edwards Lifesciences Corp. by 0.3% in the second quarter. HighTower Advisors LLC now owns 23,892 shares of the medical research company’s stock valued at $2,379,000 after buying an additional 75 shares during the last quarter. Finally, Checchi Capital Advisers LLC increased its position in Edwards Lifesciences Corp. by 3.9% in the second quarter. Checchi Capital Advisers LLC now owns 2,039 shares of the medical research company’s stock valued at $203,000 after buying an additional 76 shares during the last quarter. Institutional investors own 84.09% of the company’s stock.
Edwards Lifesciences Corp. Company Profile
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Receive News & Ratings for Edwards Lifesciences Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Edwards Lifesciences Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Edwards Lifesciences Corp. (EW) Hits New 12-Month High at $119.39"

Leave a comment

Your email address will not be published.


*